Kelli Cawley, MD
Hematology & Oncology · Belpre, OHNPI 1023113727
Payments from drug & device makers
Across 235 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$794
- Pfizer$726
- Novartis$545
- E.r. Squibb & Sons, L.L.C.$461
- Bristol Myers Squibb$218
- Genentech USA, Inc.$153
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,33692%
- Education$2868%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $794 |
| Pfizer | 53 | $726 |
| Novartis | 30 | $545 |
| E.r. Squibb & Sons, L.L.C. | 34 | $461 |
| Bristol Myers Squibb | 11 | $218 |
| Genentech USA, Inc. | 10 | $153 |
| AbbVie | 7 | $121 |
| Exelixis Inc. | 8 | $119 |
| Gilead(2 entities) | 7 | $109 |
| Amgen(2 entities) | 7 | $99 |
| GSK | 5 | $89 |
| AstraZeneca | 4 | $84 |
| Array Biopharma Inc | 6 | $78 |
| EMD Serono, Inc. | 4 | $68 |
| AVEO Pharmaceuticals, Inc. | 3 | $64 |
| Johnson & Johnson | 4 | $59 |
| Puma Biotechnology, Inc. | 2 | $56 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $54 |
| Kyowa Kirin, Inc. | 3 | $45 |
| Astellas Pharma US Inc | 3 | $45 |
| Myovant Sciences Inc. | 3 | $44 |
| Rigel Pharmaceuticals, Inc. | 3 | $43 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| AMAG Pharmaceuticals, Inc. | 2 | $38 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| ADC Therapeutics America, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Nuvation Bio Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$4,387 in reported general payments places this provider in the 45th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 58 | $1,015,266 |
| ImbruvicaIbrutinib | 52 | $812,248 |
| PomalystPomalidomide | 29 | $640,771 |
| BrukinsaZanubrutinib | 44 | $564,775 |
| Lenalidomide | 36 | $428,948 |
| JakafiRuxolitinib Phosphate | 25 | $402,242 |
| LynparzaOlaparib | 20 | $315,213 |
| SprycelDasatinib | 18 | $314,567 |
| XtandiEnzalutamide | 14 | $292,606 |
| CabometyxCabozantinib S-Malate | 12 | $278,465 |
| IbrancePalbociclib | 18 | $274,897 |
| TasignaNilotinib Hcl | 16 | $274,598 |
| ScemblixAsciminib Hydrochloride | 12 | $244,931 |
| DopteletAvatrombopag Maleate | 18 | $227,573 |
| ErleadaApalutamide | 14 | $209,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $218 | $1,015,26658 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $461 | $955,33847 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $54 | $812,24852 claims |
| NovartisTasigna, Scemblix, Mekinist | $545 | $661,72243 claims |
| PfizerIbrance, Eliquis | $726 | $459,120269 claims |
| AstraZenecaLynparza, Calquence | $84 | $418,27032 claims |
| Johnson & JohnsonErleada, Xarelto | $59 | $316,690160 claims |
| Astellas Pharma US IncXtandi | $45 | $292,60614 claims |
| Exelixis Inc.Cabometyx | $119 | $278,46512 claims |
| AbbVieVenclexta | $121 | $175,84342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Belpre
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.